Trial Profile
A retrospective, Observational, real-world study to compare the safety and efficacy of apixaban versus warfarin in patients with non-valvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- 30 Aug 2017 Results comparing the incidences of stroke/systemic embolism (S/SE) and major bleeding (MB) between standard dose/lower dose apixaban and warfarin in non-valvular atrial fibrillation patients presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 30 Aug 2017 Results of high-risk subgroups presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 25 Mar 2017 New trial record